Press release
Deadline on Oct. 2nd coming up in Lawsuit for certain Investors in Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
A Deadline is coming up on October 2, 2023 in the lawsuit for certain investors in Apellis Pharmaceuticals, Inc. (NASDAQ: APLS).
Investors who purchased shares of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) have certain options and there are strict and short deadlines running. Deadline: October 2, 2023. Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
According to the complaint filed in the U.S. District Court for the District of Delaware the plaintiff alleges on behalf of purchasers of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) common shares between January 28, 2021, and July 28, 2023, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between January 28, 2021, and July 28, 2023, the Defendants misrepresented and/or failed to disclose that the design of SYFOVRE's clinical trials was insufficient to identify incidents of retinal vasculitis in patients receiving SYFOVRE injections, that as a result, the commercial adoption of SYFOVRE was subject to significant, unknown risk factors, and that therefore, Defendants' statements about the company's business, operations, and prospects lacked a reasonable basis.
Those who purchased shares of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Deadline on Oct. 2nd coming up in Lawsuit for certain Investors in Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) here
News-ID: 3227967 • Views: …
More Releases from Shareholders Foundation
ALERT: Lawsuit filed for Investors who SOLD shares of Sina Corporation (formerly …
An investor, who sold shares of Sina Corporation (formerly NASDAQ: SINA) in the merger between Seina Corporation and TuSimple Holdings, Inc, filed a lawsuit over alleged violations of Federal Securities Laws by Sina Corporation (formerly NASDAQ: SINA in connection with certain allegedly false and misleading statements made.
If you sold a significant amount of shares of Sina Corporation (formerly NASDAQ: SINA) between October 13, 2020 and March 22, 2021, you have…
Lawsuit Alert: Investors who lost money with shares of Fluor Corporation (NYSE: …
An investor, who purchased shares of Fluor Corporation (NYSE: FLR), filed a lawsuit alleged violations of Federal Securities Laws by Fluor Corporation in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Fluor Corporation (NYSE: FLR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 14, 2025. NYSE: FLR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779…
Investigation announced for Long-Term Investors in shares of Sable Offshore Corp …
An investigation was announced for long-term investors in shares of Sable Offshore Corp. (NYSE: SOC) concerning potential breaches of fiduciary duties by certain directors of Sable Offshore Corp.
Investors who are current long term investors in Sable Offshore Corp. (NYSE: SOC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in…
Lawsuit filed for Investors who lost money with shares of Lantheus Holdings, Inc …
An investor, who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH), filed a lawsuit over alleged violations of Federal Securities Laws by Lantheus Holdings, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) have certain options and for certain investors are short and strict deadlines running. Deadline: November 10, 2025. NASDAQ: LNTH investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
More Releases for Apellis
Eylea Market Future Business Opportunities 2025-2032 | Bayer AG, Bausch + Lomb, …
The Global Eylea Market is estimated to be valued at USD 838.6 Mn in 2025 and is expected to reach USD 673.7 Mn by 2032, declining at a negative compound annual growth rate (CAGR) of -3.1% from 2025 to 2032. This Eylea market size projection aligns with rising prevalence of diabetic retinopathy and age-related macular degeneration.
The ophthalmology therapeutics industry has been revolutionized by targeted anti-VEGF agents, with Eylea commanding a…
Dense Deposit Disease Market Forecasted to Surge in Coming Years, 2024-2034 Anal …
DelveInsight's "Dense Deposit Disease Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Dense Deposit Disease, historical and forecasted epidemiology as well as the Dense Deposit Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Dense Deposit Disease, offering comprehensive insights into the Dense Deposit Disease revenue trends,…
Complement 3 glomerulopathy Market: Epidemiology, Therapies, Companies, DelveIns …
Complement 3 glomerulopathy emerging therapies, such as Iptacopan (LNP023), Pegcetacoplan (APL-2), and others, are expected to boost the Complement 3 glomerulopathy Market in the upcoming years.
DelveInsight has launched a new report on "Complement 3 glomerulopathy - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Complement 3 glomerulopathy, historical and forecasted epidemiology as well as the Complement 3 glomerulopathy market trends in the United States, EU5…
Paroxysmal Nocturnal Hemoglobinuria Treatment Market Is Booming So Rapidly | Nov …
The latest study released on the Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market by USD Analytics Market evaluates market size, trend, and forecast to 2032. The Paroxysmal Nocturnal Hemoglobinuria Treatment market study covers significant research data and proofs to be a handy resource document for managers, analysts, industry experts and other key people to have ready-to-access and self-analyzed study to help understand market trends, growth drivers, opportunities and upcoming challenges and…
Pegcetacoplan (APL-2) by Apellis Pharmaceuticals expected to drive market growth …
[Las Vegas, United States] DelveInsight, a leader in healthcare research firm, has recently published an in-depth report on Pegcetacoplan (APL-2) (Apellis Pharmaceuticals) providing insights into the drug market landscape and market forecast of Pegcetacoplan (APL-2) upto 2032. The report, titled "Pegcetacoplan (APL-2) Market Size, Forecast, and Emerging Insight - 2032" is now available for review and analysis.
Are you interested in finding out the projected market size of Pegcetacoplan (APL-2)…
Investigation announced for Long-Term Investors in shares of Apellis Pharmaceuti …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Apellis Pharmaceuticals, Inc.
Investors who are current long term investors in Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: APLS stocks follows a lawsuit filed against Apellis Pharmaceuticals,…
